BPC-157: What the Research Actually Shows
BPC-157 GI and Gut Health
150+ Animal Studies
BPC-157 has been tested in over 150 preclinical studies across tendons, gastric ulcers, fistulas, spinal cord injuries, and brain ischemia. A 2025 systematic review found only 1 clinical study among 544 screened articles.
Vasireddi et al., HSS Journal, 2025
Vasireddi et al., HSS Journal, 2025
View as imageA 15-amino-acid peptide fragment derived from human gastric juice has generated over 150 published animal studies, three human pilot studies, and one of the largest gaps between public enthusiasm and clinical evidence in modern peptide research. BPC-157 (Body Protection Compound 157) has shown consistent biological activity in rats and mice across an unusually wide range of injury models. A 2025 systematic review in the HSS Journal screened 544 BPC-157 articles and found that 35 of 36 studies meeting inclusion criteria were conducted in animals.[1] That ratio defines the current state of BPC-157 science. For the full evidence audit, including publication patterns and conflict-of-interest questions, see The Real BPC-157 Story: 544 Papers, 30 Human Subjects, 50 Million Views.
Key Takeaways
- A 2025 systematic review screened 544 BPC-157 articles; 35 of 36 included studies were in animals, 1 was clinical (Vasireddi et al., HSS Journal, 2025)
- BPC-157 activates VEGFR2 and eNOS pathways, promoting angiogenesis and nitric oxide production in endothelial cells (Hsieh et al., Scientific Reports, 2020)
- Rat Achilles tendon studies showed accelerated healing with increased tendon outgrowth and growth hormone receptor expression (Staresinic et al., 2003; Chang et al., 2014)
- Gastric protection against NSAIDs, ethanol, and stress-induced ulcers is the most replicated finding across dozens of studies since 1993
- A 2025 literature and patent review cataloged effects across 12+ organ systems, calling the evidence base "unprecedented" for a single peptide (Jozwiak et al., Pharmaceuticals, 2025)
- No regulatory agency worldwide has approved BPC-157 for any indication; the FDA classified it as Category 2 in 2023
What Is BPC-157?
BPC-157 is a synthetic pentadecapeptide with the amino acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV). Its molecular weight is 1,419.53 daltons. The peptide is a fragment of a larger protein called BPC (Body Protection Compound) that occurs in human gastric juice.
The "157" designation refers to the specific 15-amino-acid sequence selected for study. BPC-157 does not exist in this exact form in the human body. It was isolated and synthesized by researchers at the University of Zagreb in Croatia, who first published on its gastroprotective properties in 1993.[2] In pharmaceutical development contexts, BPC-157 has been assigned several designations: PL-10, PLD-116, and PL14736, all tied to clinical development programs by the Croatian pharmaceutical company Pliva.
The peptide is commercially available in two salt forms: BPC-157 acetate and BPC-157 arginate. The acetate salt is more common in research settings. The arginate form pairs BPC-157 with L-arginine, a nitric oxide precursor, which some researchers have speculated could enhance BPC-157's NO-mediated effects, though no head-to-head comparison has been published in peer-reviewed literature.
One property that set BPC-157 apart early is its stability in gastric acid. Most peptides degrade within minutes in the stomach's acidic environment. BPC-157 remains intact for over 24 hours in human gastric juice, which is unusual for a peptide of this size. In rat studies, both oral (intragastric) and injected (intraperitoneal) routes produced biological effects, though the relative bioavailability of oral BPC-157 in humans has not been established. That stability opened a question that remains partially answered: whether an orally administered peptide could retain biological activity after passing through the GI tract. For the evidence on that specific question, see Can You Take BPC-157 Orally? The Gastric Stability Evidence.
How BPC-157 Works in Lab Studies
BPC-157's proposed mechanism of action involves several overlapping pathways, most characterized in cell culture and rat models.
The VEGFR2 Pathway
The primary pathway identified is activation of VEGF receptor 2 (VEGFR2). Hsieh and colleagues at Taipei Medical University demonstrated in 2020 that BPC-157 activates two distinct routes to nitric oxide (NO) production: a VEGF-dependent pathway (VEGFR2-PI3K-Akt-eNOS) and a VEGF-independent pathway (Src-Caveolin-1-eNOS).[3] In human umbilical vein endothelial cells (HUVECs), BPC-157 stimulated phosphorylation of caveolin-1, reduced its binding to eNOS, and increased NO production. This dual-pathway activation promotes angiogenesis, the formation of new blood vessels, which is central to tissue repair.
Nitric Oxide System
The NO system appears throughout BPC-157 research. A 2014 review by Sikiric mapped the relationship between BPC-157 and NO signaling, documenting how the peptide modulates both NOS1 (neuronal) and NOS3 (endothelial) nitric oxide synthase activity.[4] In animal models, BPC-157 counteracted L-NAME-induced lesions (L-NAME blocks NO production) and modulated the effects of L-arginine (which increases NO). The pattern suggests BPC-157 does not simply increase or decrease NO but acts as a modulator, restoring balance in either direction.
Growth Hormone Receptor Expression
Chang and colleagues in Taiwan showed in 2014 that BPC-157 increased growth hormone receptor (GHR) expression in rat tendon fibroblasts by 4-fold compared to controls.[5] This study is significant because it was conducted independently of the Zagreb group and proposes a specific molecular mechanism for BPC-157's tendon-healing effects: by increasing GHR density on tendon cells, the peptide may amplify the tissue's response to circulating growth hormone. For more on how BPC-157 may protect the gut lining, the proposed mechanisms are covered in depth.
Musculoskeletal Healing Evidence
Musculoskeletal injury repair is the domain with the most diverse preclinical data. A 2019 review by Gwyer and colleagues summarized BPC-157's effects across tendon, ligament, bone, and muscle injury models.[6]
Tendons
Staresinic and colleagues published the most-cited tendon study in 2003, testing BPC-157 on transected rat Achilles tendons.[7] Treated rats showed accelerated healing with biomechanically stronger repair tissue compared to saline controls. Histological analysis revealed increased tendocyte proliferation and organized collagen fiber alignment in the BPC-157 group. Chang et al. (2011) extended this work, demonstrating that BPC-157 promoted tendon outgrowth from cultured tendon explants and increased type I collagen production.[8] The tendon outgrowth was dose-dependent and accompanied by migration of tendon cells from explant edges into surrounding matrix. A 2010 study from the Zagreb group (Staresinic et al.) also demonstrated BPC-157's positive effects on ligament healing using a medial collateral ligament transection model in rats, showing improved biomechanical properties at 14 days post-injury.
Bone
Sebecic and colleagues (1999) tested BPC-157 on segmental bone defects in rabbits and found enhanced osteogenic activity at the fracture site.[9] New bone formation was increased compared to controls, though the study used a small sample and has not been widely replicated.
Muscle
A 2022 review by Staresinic cataloged BPC-157's effects on striated muscle, smooth muscle, and cardiac muscle across multiple animal models.[10] Effects included accelerated healing after muscle crush injuries, reduced fibrosis in healing muscle, and protective effects against doxorubicin-induced cardiac damage. Most of these findings come from the Zagreb group and await independent confirmation.
The Systematic Evidence
The 2025 systematic review by Vasireddi et al. provides the most rigorous accounting of this domain.[1] Of 36 studies meeting inclusion criteria, findings were consistently positive across injury types. The reviewers noted that while the preclinical signal is strong, the absence of controlled human trials means no evidence-based clinical recommendations can be made. A 2025 literature and patent review by Jozwiak et al. cataloged BPC-157 effects across 12 or more organ systems and called the breadth of activity "unprecedented" for a single peptide, while acknowledging the same translational gap.[11]
Gastrointestinal Protection and Repair
Gastric protection is where BPC-157 research began and where the evidence is deepest.
Gastric Ulcers
BPC-157 was first characterized as a gastroprotective agent in 1993.[2] Dozens of subsequent studies tested it against ulcers induced by NSAIDs, ethanol, restraint stress, cysteamine, and corticosteroids. The protective effect against NSAID-induced gastric damage is the single most replicated finding in the BPC-157 literature, documented across multiple NSAID types (diclofenac, ibuprofen, celecoxib) and multiple study designs. For the full animal evidence, see BPC-157 and Gastric Ulcers: The Animal Study Evidence.
Intestinal Permeability
Park and colleagues (2020) demonstrated that BPC-157 rescued NSAID-induced intestinal permeability damage in cell culture and animal models.[12] The study showed stabilization of tight junction proteins and enhanced expression of cytoprotective heat shock protein 70 (HSP70). This finding is relevant to the concept of "leaky gut," though that term oversimplifies the complex biology of intestinal barrier function. More on this at BPC-157 and Leaky Gut: Can a Peptide Restore Intestinal Permeability?
Inflammatory Bowel Disease
A 2012 review by Sikiric specifically examined BPC-157's potential relevance to ulcerative colitis, summarizing positive effects in multiple rat colitis models including TNBS-induced colitis, cysteamine-induced colitis, and stress-induced colitis.[13] The review noted that BPC-157 had entered human trials for UC (the Pliva-sponsored Phase II), but as covered in The Ghost Trial: What Happened to BPC-157's Phase II for UC?, those results were never published. For the full IBD picture, see BPC-157 for Inflammatory Bowel Disease: What We Know So Far.
Fistula Healing
Multiple animal studies have tested BPC-157 on various fistula types: gastrocutaneous, rectovaginal, colovesical, esophagocutaneous, vesicovaginal, and duodenocolic. A 2021 review by Seiwerth cataloged these results alongside broader wound-healing data.[14] Across all fistula models tested, BPC-157-treated animals showed accelerated closure compared to controls. For esophageal-specific research, see BPC-157 for Esophageal Damage: Research on Acid Reflux Injury.
Neuroprotective and CNS Effects
BPC-157's effects extend beyond wound healing into the central nervous system.
Brain and Spinal Cord
Vukojevic and colleagues published a 2022 review covering BPC-157's documented CNS effects across multiple animal models.[15] The evidence includes reduced damage in traumatic brain injury models, attenuation of dopaminergic system disturbances (relevant to Parkinson's disease models), anxiolytic effects in stressed rats, and antidepressant-like effects in the Porsolt swim test. Perovic et al. (2019) showed improved functional recovery in a rat spinal cord injury model treated with BPC-157 compared to controls.[16]
Hippocampal Ischemia
Vukojevic et al. (2020) tested BPC-157 in a rat hippocampal ischemia-reperfusion model.[17] BPC-157-treated rats showed reduced neuronal loss in the CA1 region and better performance on memory tasks compared to untreated controls. The study used both intraperitoneal and intragastric administration routes, with positive effects observed in both.
These CNS findings connect to BPC-157's broader influence on the gut-brain axis, a topic covered in BPC-157 and the Gut-Brain Axis: Digestive and Neurological Connections.
Cardiovascular and Blood Vessel Effects
BPC-157's pro-angiogenic properties have cardiovascular implications.
Seiwerth and colleagues (2014) reviewed BPC-157's effects on blood vessel formation and repair, documenting accelerated vessel growth in multiple wound models.[18] The VEGFR2-mediated mechanism drives new vessel formation at injury sites, which supports tissue repair but raises a theoretical question: could a compound that promotes blood vessel growth also promote tumor vascularization? No study has shown BPC-157 promoting tumor growth, but no study has specifically tested long-term cancer safety either.
BPC-157 also affected hemostasis. Stupnisek et al. (2012) found that BPC-157 reduced bleeding time and counteracted thrombocytopenia after limb amputation in rats treated with anticoagulants.[19] The effect appeared to involve platelet function rather than coagulation cascade factors.
The Human Evidence
Three human studies exist. All were published by the same author, Edwin Lee, in the same journal, Alternative Therapies in Health and Medicine. No independent investigator has published human BPC-157 data.
The first (2021) tested intra-articular BPC-157 injections for chronic knee pain in 12 patients. Seven reported pain relief lasting more than six months. There was no control group, no placebo arm, and no blinding. Outcomes were self-reported by patients who knew what they received.
The second (2024) tested BPC-157 in patients with interstitial cystitis (chronic bladder pain), reporting symptom improvement in a small, uncontrolled sample.[20] Interstitial cystitis is known for symptom fluctuation, which makes uncontrolled results difficult to interpret.
The third (2025) tested intravenous BPC-157 infusion in 2 healthy adults at doses of 10 mg and 20 mg. No adverse events were reported across cardiac, hepatic, renal, thyroid, or glucose biomarkers.[21] The purpose was safety, not efficacy, and with 2 subjects the study can only establish that those specific individuals tolerated the infusion.
None of these three studies were randomized controlled trials. All appeared in a journal that does not carry the same peer review rigor as major medical journals. Approximately 30 total humans have been studied across all three pilots. For comparison, semaglutide went through Phase III trials with thousands of patients across multiple countries before receiving approval. The gap between BPC-157's animal evidence and its human evidence is covered in detail in The Limits of BPC-157 Research: Why We Don't Have Human Trial Data Yet.
The Research Concentration Problem
Over 80% of BPC-157 publications originate from a single laboratory at the University of Zagreb, led by Predrag Sikiric. In standard science, a finding requires independent replication before it is considered established. For BPC-157, that replication is sparse. The Taiwanese studies by Chang et al. and the 2020 Hsieh et al. mechanism study represent meaningful independent work, but they are exceptions. Sikiric is also CEO of Diagen, a company holding BPC-157 patents, a financial interest not disclosed in his published papers. For a full examination of this issue, see The Real BPC-157 Story. China's military research establishment has also studied BPC-157, covered in The Chinese Military's BPC-157 Program.
Safety and Regulatory Status
What the Preclinical Data Shows
The 2020 Sikiric review noted that across hundreds of animal experiments spanning 27 years, no toxic effects from BPC-157 administration have been reported.[22] In rats, doses up to 10 mg/kg produced no acute toxicity, genotoxicity, or hemolytic effects. The LD50 (dose required to kill 50% of test animals) has not been established because no lethal dose has been identified in published research.
That said, "no observed toxicity in rats" is a limited safety statement. Rat studies test acute and short-term effects. Chronic exposure data, reproductive toxicity data, and carcinogenicity data are absent from the published literature.
Regulatory Position
No regulatory agency has approved BPC-157 for any indication in any country. In 2023, the U.S. Food and Drug Administration classified BPC-157 as a Category 2 bulk drug substance, citing potential immunogenicity, manufacturing impurity risks, and insufficient human safety data. Licensed compounding pharmacies cannot legally produce it. The World Anti-Doping Agency (WADA) added BPC-157 to its prohibited list in 2022. Athletes who test positive face sanctions.
BPC-157 remains available through online suppliers who label it "for research purposes only." These products are not regulated for purity, sterility, or accurate peptide content. For additional context on anti-doping implications, a planned article covers BPC-157 and TB-500 in Sports: Anti-Doping Status Explained.
What the Evidence Adds Up To
BPC-157 has a preclinical record that is extensive in scope and consistent in direction. Across tendons, gastric mucosa, intestinal barriers, fistulas, spinal cord, and brain tissue, the peptide shows healing-promoting effects in animal models. The mechanisms involve VEGFR2-mediated angiogenesis, NO system modulation, and growth hormone receptor upregulation, pathways that have been characterized by both the originating Zagreb group and independent labs in Taiwan.
What BPC-157 does not have is the clinical evidence required to know whether these effects translate to humans. Three uncontrolled pilot studies in roughly 30 subjects, published by one investigator in one journal, represent the entire human dataset. The single Phase II trial that was conducted for ulcerative colitis never published results. No pharmaceutical company is currently running large-scale BPC-157 trials, and the FDA's Category 2 classification adds a regulatory barrier to clinical development in the United States.
The peptide's story is one of genuine biological activity paired with a translational gap that has persisted for three decades. Whether that gap will close depends on clinical trials that do not yet exist.
The Bottom Line
BPC-157 has over 150 animal studies showing consistent healing effects across musculoskeletal, gastrointestinal, and neurological injury models, driven primarily by VEGFR2-mediated angiogenesis and NO system modulation. The human evidence consists of three uncontrolled pilot studies totaling roughly 30 subjects. No regulatory agency has approved BPC-157 for any use, and the translational gap between animal and human data remains the defining feature of this peptide's evidence base.